Clinical trials: aldesleukin
Kidney Cancer
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00853021
- Testing
- aldesleukin, bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jorge A. Garcia, MD
Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
This phase II trial studies the side effects and how well white blood cells taken from person's own (autologous) cluster of differentiation (CD)8+ antigen-specific T cells, cyclophosphamide, aldesleukin, and ipilimumab work in…
- Trial name
- NCT02027935
- Testing
- Aldesleukin, Autologous CD8+ Melanoma Specific T Cells, Cyclophosphamide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of the drug Yervoy (ipilimumab) that can be given with the drugs Temodar (temozolomide), Intron-A (interferon alfa-2b), Proleukin…
- Trial name
- NCT01409174
- Testing
- Ipilimumab, Temozolomide, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm
Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies
This phase I trial studies the side effects and best dose of donor cord blood T-cells after stem cell transplant in treating patients with relapsed hematological malignancies.
- Trial name
- NCT01630564
- Testing
- Aldesleukin, Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion, Umbilical Cord Blood-Derived Lymphocyte Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides or Sezary syndrome.
- Trial name
- NCT00005788
- Testing
- aldesleukin
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Colorectal Cancer, Hematologic Malignancy
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers.
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia
- Trial name
- NCT05400122
- Testing
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- David Wald
Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the…
- Conditions
- Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma
- Trial name
- NCT02133196
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005537
- Testing
- aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide
- Sponsor
- Fred Hutchinson Cancer Center
Alzheimer Disease
Low Dose IL2 Immunotherapy in AD
Neuroinflammation is a significant component of Alzheimer disease (AD). Our data demonstrated compromised regulatory T cells (Tregs) phenotype and suppressive function in AD patients, skewing the immune system toward a…
- Trial name
- NCT05821153
- Testing
- Aldesleukin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- The Methodist Hospital Research Institute
Myelodysplastic Syndromes
Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes
A phase I study of azacitidine with Ceplene/interleukin-2 will first evaluate the safety and tolerability of this regimen in patients with higher risk myelodysplastic syndromes (MDS) who achieved a hematological response after 6…
- Trial name
- NCT01324960
- Testing
- Ceplene®, IL-2, Azacitidine, Azacitidine
- Where
- 28 sites in France
- Sponsor
- Groupe Francophone des Myelodysplasies
Metastatic Melanoma
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
This is a research study to evaluate treatment of metastatic melanoma patients with a combination of drugs. The combination being studied is vemurafenib (also known as Zelboraf®) and High Dose Interleukin-2 (abbreviated as HD…
- Trial name
- PROCLIVITY01 (NCT01683188)
- Testing
- vemurafenib + HD IL-2
- Where
- 21 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clinigen, Inc.
Metastatic Melanoma
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.
- Trial name
- PROCLIVITY02 (NCT01856023)
- Testing
- High Dose Interleukin-2, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- Clinigen, Inc.
Leukemia, Myelodysplastic Syndromes
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients with myelodysplastic syndrome.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002746
- Testing
- aldesleukin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Washington
Melanoma
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Background: Cell therapy is an experimental cancer therapy. It takes young tumor infiltrating lymphocytes (Young TIL) cells from a person s tumors and grows them in a lab. Then they are returned to the person.
- Trial name
- NCT02621021
- Testing
- young TIL, Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections, Hepatitis C
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
This study will test the safety and effectiveness of a new treatment for hepatitis C (HCV) in patients who also have HIV. The usual treatment for HCV in people who are not HIV-infected is interferon-alfa (IFN) with ribavirin…
- Trial name
- NCT00015652
- Testing
- Ribavirin, Aldesleukin, Peginterferon alfa-2b
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sjögren's Syndrome
Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome
The purpose of this paper is to analysis of therapeutic effect and immunological mechanism of low-dose IL-2 combined with rapamycin in the treatment of Sjogren's syndrome
- Trial name
- NCT05605665
- Testing
- low-dose interleukin-2, rapamycin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Neuroblastoma
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
Primary: Evaluate safety, feasibility, persistence, and anti-tumor effect of infused haploidentical donor-derived natural killer (NK) cells and low-dose interleukin-2 (IL-2).
- Trial name
- NCT00698009
- Testing
- Fludarabine, Cyclophosphamide, Natural Killer Cell Infusion
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Advanced Malignant Solid Tumor
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.
- Trial name
- NCT07389239
- Testing
- Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Chicago